DDInter458 DDInter1376
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Cyclosporine {u} (Compound) treats {v} (Disease) focal segmental glomerulosclerosis
Cyclosporine {u} (Compound) binds {v} (Gene) SLC10A2
Cyclosporine {u} (Compound) upregulates {v} (Gene) IFRD1
Cyclosporine {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
Cyclosporine {u} (Compound) downregulates {v} (Gene) CENPF
Cyclosporine {u} (Compound) causes {v} (Side Effect) Injury
Cyclosporine {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PPIB
Cyclosporine (Compound) treats focal segmental glomerulosclerosis (Disease)
Cyclosporine (Compound) binds SLC10A2 (Gene)
Cyclosporine (Compound) upregulates IFRD1 (Gene)
Cyclosporine (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class)
Cyclosporine (Compound) downregulates CENPF (Gene)
Cyclosporine (Compound) causes Injury (Side Effect)
Cyclosporine (Compound) binds PPIB (Gene) and Cyclosporine (Compound) upregulates PPIB (Gene)